Synergy Pharmaceuticals (NASDAQ:SGYP) : 2 analysts are covering Synergy Pharmaceuticals (NASDAQ:SGYP) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels.
Synergy Pharmaceuticals (NASDAQ:SGYP) : Average target price received by Synergy Pharmaceuticals (NASDAQ:SGYP) is $10.75 with an expected standard deviation of $6.01. The most aggressive target on the stock is $15, whereas the most downbeat target is $7. 2 financial analysts are currently covering the stock.
For the current week, the company shares have a recommendation consensus of Buy. Also, Major Brokerage house, Rodman & Renshaw maintains its ratings on Synergy Pharmaceuticals (NASDAQ:SGYP). In the latest research report, Rodman & Renshaw lowers the target price from $16 per share to $15 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on May 9, 2016.
Synergy Pharmaceuticals (NASDAQ:SGYP): stock turned positive on Tuesday. Though the stock opened at $3.55, the bulls momentum made the stock top out at $3.63 level for the day. The stock recorded a low of $3.52 and closed the trading day at $3.63, in the green by 6.76%. The total traded volume for the day was 2,533,465. The stock had closed at $3.4 in the previous days trading.
In an insider trading activity, Denoyer Bernard, officer (Senior Vice President, Finance) of Synergy Pharmaceuticals, Inc., unloaded 10,000 shares at an average price of $7.5 on September 14, 2015. The total amount of the transaction was worth $75,000, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.